ofatumumab

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

KESIMPTA — NOVARTIS, approved 2026-04-01 (BLA125326).

Most reported adverse events (US / FAERS)

36,800 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

fatigue

5,478

headache

4,593

pyrexia

3,535

pain

3,524

chills

Medicines containing this active substance

2 medicines

🇺🇸 Also approved in the US (FDA)

KESIMPTA — NOVARTIS, approved 2026-04-01 (BLA125326).

Most reported adverse events (US / FAERS)

36,800 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

fatigue

5,478

headache

4,593

pyrexia

3,535

pain

3,524

chills

3,459

influenza like illness

2,850

nausea

1,791

multiple sclerosis relapse

1,661

covid-19

1,515

asthenia

1,477

multiple sclerosis

1,439

gait disturbance

1,414

hypoaesthesia

1,379

feeling abnormal

1,345

malaise

1,340